StockMarketWire.com - ANGLE, the specialist medtech company, says results of the University of Southern California (USC) Norris Comprehensive Cancer Centre's ongoing work with ANGLE's Parsortix system have demonstrated the potential for the use of Parsortix as a liquid biopsy for metastatic breast cancer.

USC head to head patient data will be presented today at AACR 2016 (the American Association for Cancer Research Annual Meeting 2016), which demonstrates a statistically significant correlation in metastatic breast cancer between analysis of CTCs (circulating tumor cells) harvested from a simple blood test using Parsortix with similar analysis of tissue obtained from invasive biopsy of a secondary cancer site.

The Directors believe that the data demonstrates the potential for the Parsortix liquid biopsy (simple blood test) to replace the invasive biopsy.

At 9:58am: [LON:AGL] Angle PLC share price was 0p at 73p



Story provided by StockMarketWire.com